Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: A three-way crossover study

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 9, 2011, Pages 1351-1358

  Fogari, Roberto ^a   Zoppi, Annalisa ^a   Mugellini, Amedeo ^a   Maffioli, Pamela ^a   Lazzari, Pierangelo ^a   Monti, Claudio ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Aliskiren; amlodipine; ankle edema; hypertension

Indexed keywords

ALISKIREN; AMLODIPINE;

ADULT; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FLUID RETENTION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PLASMA RENIN ACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPHYGMOMANOMETRY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AMIDES; AMLODIPINE; ANKLE; ANKLE JOINT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EDEMA; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NOREPINEPHRINE; PROSPECTIVE STUDIES; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 79956113335     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.580276     Document Type: Article

References (37)

1. Opie LH. Calcium channel antagonists. Part IV: side effects and contraindications, drug interactions and combinations. Cardiovasc Drugs Ther 1988;2:177-89
2. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens 2003;5:330-5
3. Chrisant SG. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens 2008;10:716-22
4. Gustaffsson D, Grande PE, Borgstrom P, et al. Effects of calcium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat skeletal muscle. J Cardiovsc Pharmacol 1988;12:413-22
5. Messing M, Van Essen H, Smith TL, et al. Microvascular actions of calcium channel antagonists. Eur J Pharmacol; 1991;198:189-95
6. Salmasi AM, Belcaro G, Nicolaides AN. Impaired venoarteriolar reflex as a possible cause for nifedipine-induced ankle edema. Int J Cardiol 1991;30:303-7
7. Pedrinelli R, Dell'Olmo G, Melillo E, et al. Amlodipine, enalapril and dependent led edema in essential hypertension. Hypertension 2000;35:621-5 (Pubitemid 30108158)
8. Fogari R, Malamani GD, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel group study. Curr Ther Res Clin Exp 2000;61:850-62 (Pubitemid 32015352)
9. Fogari R. Ankle oedema and sympathetic activation. Drugs 2005;65(Suppl 2):21-7
10. Weir M, Rosenberg C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and Ace-inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001;14:963-8 (Pubitemid 32862599)
11. Guazzi MD, De Cesare N, Galli C, et al. Calcium channel blockade with nifedipine and angiotensin converting enzyme with captopril in the therapy of patients with severe primary hypertension. Circulation 1984;70:279-84 (Pubitemid 14053050)
12. Messerli FH, Oparil S, Feng Z. Comparison of the efficacy and side-effects of combination therapy of angiotensin converting enzyme inhibitor (benazeperil) with calcium antagonist (either nifedipine or amlodipine) versus high dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000;86:1182-7
13. Fogari R, Malamani GD, Zoppi A, et al. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2003;17:207-12 (Pubitemid 36388805)
14. Fogari R, Malamani GD, Zoppi A, et al. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way cross-over study. Clin Ther 2007;29:413-18 (Pubitemid 46907281)
15. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80 (Pubitemid 47028551)
16. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4
17. de la Sierra A. Mitigation of calcium canne blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens 2009;23:503-11
18. Fogari R, Malamani GD, Corradi L, et al. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Adv Ther 2010;27:48-55
19. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410 (Pubitemid 351619112)
20. Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology of rennin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure. Expectations and reality. Biochem Pharmacol 2009;78:933-40
21. Rea RF, Eckberg DL, Fritsch JM, et al. Relation of plasma norepinephrine and sympathetic traffic during hypotension in humans. Am J Physiol 1990;258:R982-6 (Pubitemid 20155599)
22. Abdelrahman AM, Burrel LM, Johnston CI. Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone. J Hypertens 1993;11(Suppl 3):S49-52
23. Hansson L, Hedner T, Dahlof B. Prospective, Randomized, Open, Blinded End point (PROBE) study: a novel design for intervention trials. Blood Press 1992;1:113-14
24. Lauderer A. Die Gewebspannung in ihren Einfluss auf die Ortliche Blut-vud Lymphbewegung. Fogel FCW, Leipzig; 1884
25. Burch GE, Sodeman WA. The estimation of subcutaneous pressure by direct method. J Clin Invest 1937;16:845-50
26. Malamani V. Modificazioni della pressione dei tessuti nell'edema provocato. Boll Soc Ital Biol Sper 1947;23:125-31
27. Malamani V. La pressione dei tessuti. Tipografia Popolare, Pavia; 1957
28. Remie R, Zaagsma J. A new technique for the study of vascular presynaptic receptors in freely moving rats. Heart Circ Physiol 1986;251:4463-7
29. Hjemdahl P. Plasma catecholamines as markers for sympathoadrenal activity in human primary hypertension. Pharmacol Toxicol 1988;63(Suppl 1):S27-31
30. Nussberger J, Fasanella d'Amore T, Porchet M, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987;9:39-44 (Pubitemid 17212750)
31. Pelet C, Mironneau C, Rakotoarisoa L, et al. Angiotensin II receptor subtypes inportal vein smooth muscle. Eur J Pharmacol 1995;279:15-24
32. Fernades L, Loiola RA, Tostes RCA, et al. Angiotensin II-induced venoconstriction involves both AT1 and AT2 receptors and is counterbalanced by nitric oxide. Peptides 2005;26:2458-63 (Pubitemid 41676717)
33. Tabizchi R, King KA, Pang CC. Direct and indirect effects of angiotensin II on venous tone in conscious rats. Eur J Pharmacol 1992;219:141-5
34. Rothe CF, Maass-Moreno R. Active and passive liver microvascular responses from angiotensin, endothelin, norepinephrine and vasopressin. Am J Physiol 2000;279:H1147-56
35. Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular disorders: do we need a more comprehensive strategy? Rev Cardiovasc Med 2006;7:45-54
36. Drummond W, Munger MA, Rafique Essop M, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007;9:742-50
37. Littlejohn TW III, Trenkwalder P, Hollanders G, et al. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009;25:951-9